Morgan Stanley Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) Stock

Celldex Therapeutics (NASDAQ:CLDX) had its price objective lifted by equities research analysts at Morgan Stanley from $50.00 to $57.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target indicates a potential upside of 70.10% from the company’s current price.

CLDX has been the topic of a number of other research reports. Stifel Nicolaus set a $68.00 price target on Celldex Therapeutics in a research report on Tuesday. Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Wells Fargo & Company increased their target price on Celldex Therapeutics from $48.00 to $72.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. UBS Group raised their price target on Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Finally, Guggenheim lifted their price target on Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.75.

Celldex Therapeutics Stock Down 11.6%

CLDX opened at $33.51 on Wednesday. The company has a market capitalization of $2.63 billion, a price-to-earnings ratio of -7.70 and a beta of 0.84. The firm has a 50-day moving average price of $39.03 and a 200-day moving average price of $34.84. Celldex Therapeutics has a twelve month low of $22.10 and a twelve month high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.12. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.73 million. On average, sell-side analysts expect that Celldex Therapeutics will post -4.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CLDX. Nykredit A S bought a new stake in Celldex Therapeutics in the second quarter valued at $67,000. Diversified Trust Co purchased a new stake in Celldex Therapeutics in the first quarter worth about $223,000. Walleye Capital LLC bought a new stake in Celldex Therapeutics during the 1st quarter valued at approximately $258,000. Amundi purchased a new position in shares of Celldex Therapeutics during the 1st quarter worth approximately $297,000. Finally, ProShare Advisors LLC grew its holdings in shares of Celldex Therapeutics by 6.9% during the 4th quarter. ProShare Advisors LLC now owns 11,973 shares of the biopharmaceutical company’s stock worth $325,000 after acquiring an additional 773 shares during the period.

Key Celldex Therapeutics News

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: Barzolvolimab achieved the main goals in both Phase 3 trials. Celldex reported that EMBARQ-CSU1 and EMBARQ-CSU2 met their primary and all key secondary endpoints in chronic spontaneous urticaria, including statistically significant improvements in weekly urticaria activity scores at Week 12. Benefits were also reported in patients who had failed omalizumab and those with severe disease or angioedema. Celldex Phase 3 results announcement
• Positive Sentiment: The results support a potential 2027 regulatory filing. Celldex said efficacy was sustained or deepened through Week 24 and that both trials will continue to Week 52. Management expects to submit a biologics license application in 2027, potentially positioning barzolvolimab as a major commercial opportunity in CSU. Reuters report on Celldex trial results
• Positive Sentiment: Analysts raised their valuation targets. HC Wainwright lifted its target from $42 to $64 with a Buy rating, while Cantor Fitzgerald raised its target from $61 to $72 and maintained an Overweight rating. These targets imply substantial upside if the clinical results translate into approval and commercial success.
• Neutral Sentiment: The stock’s reaction was counterintuitive. Reports described a decline following the readout, likely reflecting profit-taking and very high expectations ahead of the catalyst rather than clearly negative efficacy data. Investors may now be shifting attention toward approval timing, launch potential and longer-term safety.
• Negative Sentiment: Safety concerns overshadowed the trial win. Some investors questioned the safety profile of barzolvolimab, even though Celldex characterized the drug as well tolerated through 24 weeks and said the profile was consistent with earlier studies. Unresolved safety concerns could affect regulatory review and the drug’s eventual market adoption. Economic Times report on safety concerns

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for diseases with significant unmet medical needs. The company’s research programs address conditions in immunology, inflammation, oncology and other areas where targeted immune-system modulation may provide therapeutic benefits.

Celldex’s lead investigational product is barzolvolimab, an antibody designed to block the KIT receptor and reduce mast cells. The therapy is being studied in immune-mediated diseases, including chronic spontaneous urticaria and prurigo nodularis.